Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    TopAbstracts in Rheumatoid Arthritis 11/13/2008 - (DGNews)
    Declining Benefit of Combination Therapy for Rheumatoid Arthritis Found in Long-Term Follow-Up of Patients: Presented at ACR-ARHP - (DGDispatch)
    Genetic Markers Point to Increased Risk of Infection in Patients With Rheumatoid Arthritis: Presented at ACR-ARHP - (DGDispatch)
    Efficacy of Rituximab Is Sustained in Patients With Rheumatoid Arthritis: Presented at ACR-ARHP - (DGDispatch)
    Tocilizumab Is Effective for Rheumatoid Arthritis in Patients With Inadequate Response to Prior Anti-TNF Treatment: Presented at ACR-ARHP - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
      B-Cell Biology and B-Cell-Targeted Therapies for Autoimmune Rheumatic Diseases: The Role of the Allied Health Professional
      Advances in B-Cell Biology in the Treatment of Autoimmune and Inflammatory Diseases
      The Management of Difficult Rheumatoid Arthritis
      Expanding the Armamentarium for the Treatment of Juvenile Rheumatoid Arthritis: Update for Managed Care Pharmacists
      Hepatic Effects of Biologic Agents: Current and Future Issues in the Treatment of Rheumatoid Arthritis

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Disseminated Cutaneous Herpes Simplex Virus-1 in a Patient with Rheumatoid Arthritis Receiving Infliximab: A Case Report
        Rheumatoid Nodule of the Thyrohyoid Membrane: A Case Report
        Recurrent Pneumothorax in a Patient with Rheumatoid Arthritis on Leflunomide Treatment: Case Report and Overview of the Literature
        Spontaneous Esophageal Perforation in a Patient with Achalasia Cardia and Rheumatoid Arthritis
        Rheumatoid Arthritis in Thalassemia Intermedia: Coincidence or Association?

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Folic Acid Supplementation Recommended In Methotrexate Treatment Of Rheumatoid Arthritis

        A DGReview of :"Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review"
        Rheumatology

        01/21/2004
        By Jill Taylor


        Folic acid supplementation in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX) improves tolerability, does not compromise efficacy, and may reduce the risk of cardiovascular disease, according to a British study.

        MTX is the most commonly used disease-modifying anti-rheumatic drug (DMARD) in RA treatment. However, there is a 30% probability of MTX discontinuation 1 year after initiation of therapy, with side effects being the main influencing factor.

        Some of these side effects, including gastrointestinal intolerance, cytopaenias and alopecia, are similar to those seen during folate deficiency. Moreover, folate deficiency is a recognised risk factor for MTX toxicity.

        Researchers S. I. Whittle and Dr. Rod A. Hughes of the Department of Rheumatology, Ashford & St Peters NHS Trust, Chertsey, performed a review summarising current data regarding the use of supplemental folic acid in MTX therapy for RA to prevent adverse effects and potentially modulate cardiovascular risk.

        Relevant literature was identified by Medline search and reviewed. Results showed that the use of supplemental folates, including folic and folinic acid, in RA patients treated with MTX improves continuation rates by reducing the incidence of liver function test abnormalities and gastrointestinal intolerance.

        Furthermore, supplemental folic acid offsets the elevation in plasma homocysteine associated with the use of MTX, which may in turn reduce the risk of cardiovascular disease.

        Folic acid supplementation has not been shown to compromise the MTX efficacy in the treatment of RA. Alternatively, evidence suggests that under some circumstances, folinic acid may reduce MTX efficacy.

        The investigators conclude by proposing that folic acid supplements be prescribed routinely to all patients receiving MTX for the treatment of RA.

        "We recommend a single dose of 5mg of folic acid once per week, taken on the morning following the day of MTX dosing," they said. "If adverse effects still occur, an increase to a single dose of 10 mg per week may be considered."



        Rheumatology (Oxford) 2004 Jan 6;[Epub ahead of print]. "Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send